Dra. Cristina Saura Manich

Dr. Saura graduated in Medicine from the University of Barcelona (UB) in 2002. From 2003 to 2007 she completed her internship in Medical Oncology at Vall d’Hebron Hospital in Barcelona.
In 2007, dr. Saura obtained her Master of Advanced Studies with the project “Breast Cancer Early Detection Program in High-Risk Women: pilot breast mammography and breast magnetic resonance imaging tracking experience”, with an outstanding grade “A”. Her interest in clinical research led her to complete the Program in Clinical Effectiveness at Harvard School of Public Health in Boston in 2007. She subsequently earned her PhD in Medicine from the Universtat Autonoma of Barcelona (UAB) in 2017 with honors cum laude with the project entitled "Treatment of breast cancer diagnosed during pregnancy". She was awarded a grant of the Strategic Plan for Research and Innovation in Health (PERIS) from the Generalitat de Catalunya in 2018 with the project "Precision medicine in metastatic breast cancer: determination of mutations in tumors and circulating DNA as a guide for the treatment of patients with metastatic breast cancer".
Dr. Saura has participated as Principal Investigator and co-investigator in multiple clinical trials in the field of research on breast cancer driven by her interest in the development of new drugs that improve the prognosis of patients. She is currently involved in different international studies with drugs targeted against molecular targets in breast cancer. The work of dr. Saura is focused on precision medicine and she occupies a prominent position in the development of PI3K inhibitors and new anti-HER2 treatments. In the field of pregnancy-related breast cancer, she is currently leading a project on early diagnosis of breast cancer based on the presence of circulating DNA in breast milk. She is the author of multiple publications, as well as communications at different national and international congresses.
 She is a member of the Scientific Committee and Board of Directors of the cooperative breast cancer group SOLTI, a member of the Spanish Society of Medical Oncology (SEOM), and a member of GEICAM (Spanish Breast Cancer Research Group) and the European and American Oncology Societies (ESMO, ASCO).